Olga Goloubeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olga Goloubeva has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chana Weinstock
US Food and Drug Administration, Silver Spring, Maryland
1 shared publication - Cristina Campassi
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, RM S9D, Baltimore, MD 21201 USA
1 shared publication - Emily Catherine Bellavance
Department of Surgery, University of Maryland, Baltimore, MD, USA.
1 shared publication - Katherine H. Rak Tkaczuk
14University of Maryland, Baltimore, Maryland
1 shared publication - Kathleen Wooten
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, RM S9D, Baltimore, MD 21201 USA
1 shared publication - Olga Ioffe
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, RM S9D, Baltimore, MD 21201 USA
1 shared publication
Latest Publications
- Open Access
- 28 August 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 459
Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors
As the breast cancer survivor population increases, the topic of screening these women for recurrences is increasingly relevant. In our institution, we use both breast MRI and mammography in the surveillance of breast cancer survivors, although little data exists on the use of MRI in this setting. We present a retrospective analysis of our experience and compare the sensitivity and specificity of MRI vs. mammography in this setting. We identified women under 65 with a history of breast cancer and at least one follow-up MRI performed along with a mammogram done within 6 months of the MRI. We compared the outcomes of MRI and mammography in terms of biopsies performed as well as in detection of new cancers. Of 617 charts reviewed, 249 patients met inclusion criteria, with 571 paired MRI/mammogram results. There were 27 biopsies performed due to MRI findings alone, 10 done due to mammographic findings alone, and 15 done based on abnormalities seen on both imaging modalities. There were 8 malignancies identified based on an abnormal MRI, 3 detected on both MRI and mammography, and none identified via mammography alone. Overall, MRI had a sensitivity of 84.6% (the 95% CI 54.6–98.1) and a specificity of 95.3% (the 95% CI 93.3–96.9); mammography a sensitivity of 23.1% (the 95% CI 5.0–53.8), and a specificity of 96.4% (the 95% CI 94.5–97.8). Breast MRI is a useful surveillance modality in breast cancer survivors and may be more sensitive at detecting recurrences than mammography alone in this population.
- 28 August 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 459
Open AccessBreast magnetic resonance imaging (MRI) surveillance in breast cancer survivors
As the breast cancer survivor population increases, the topic of screening these women for recurrences is increasingly relevant. In our institution, we use both breast MRI and mammography in the surveillance of breast cancer survivors, although little data exists on the use of MRI in this setting. We present a retrospective analysis of our experience and compare the sensitivity and specificity of MRI vs. mammography in this setting. We identified women under 65 with a history of breast cancer and at least one follow-up MRI performed along with a mammogram done within 6 months of the MRI. We compared the outcomes of MRI and mammography in terms of biopsies performed as well as in detection of new cancers. Of 617 charts reviewed, 249 patients met inclusion criteria, with 571 paired MRI/mammogram results. There were 27 biopsies performed due to MRI findings alone, 10 done due to mammographic findings alone, and 15 done based on abnormalities seen on both imaging modalities. There were 8 malignancies identified based on an abnormal MRI, 3 detected on both MRI and mammography, and none identified via mammography alone. Overall, MRI had a sensitivity of 84.6% (the 95% CI 54.6–98.1) and a specificity of 95.3% (the 95% CI 93.3–96.9); mammography a sensitivity of 23.1% (the 95% CI 5.0–53.8), and a specificity of 96.4% (the 95% CI 94.5–97.8). Breast MRI is a useful surveillance modality in breast cancer survivors and may be more sensitive at detecting recurrences than mammography alone in this population.